Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 1;76(17):1273-1280.
doi: 10.1093/ajhp/zxz127.

Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection

Douglas D DeCarolis  1 , Yi-Chieh Chen  2 , Anders D Westanmo  3 , Christopher Conley  4 , Amy A Gravely  5 , Fatima B Khan  6
Affiliations

Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection

Douglas D DeCarolis et al. Am J Health Syst Pharm. .

Erratum in

  • Correction Notice.
    [No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Apr 1;79(8):709. doi: 10.1093/ajhp/zxz232. Am J Health Syst Pharm. 2022. PMID: 31609406 No abstract available.

Abstract

Purpose: We previously reported an interaction with warfarin anticoagulation when initiating treatment with direct-acting antiviral agents for hepatitis C infection. A decreased warfarin sensitivity led to subtherapeutic anticoagulation. To study this interaction further, we expanded our research to include patients treated with the combination of elbasvir and grazoprevir concurrent with warfarin anticoagulation and investigated changes in warfarin sensitivity during and after treatment.

Methods: Using electronic health records of the Veterans Health Administration, patients starting treatment with elbasvir-grazoprevir for hepatitis C infection concurrent with warfarin anticoagulation were identified. Inclusion required stable warfarin anticoagulation prior to 12 weeks of treatment with elbasvir-grazoprevir. A warfarin sensitivity index (WSI) was calculated at the start of treatment, after 12 weeks after treatment, and at the end of treatment. The primary endpoint was the difference in WSI from pre- to end-treatment. The secondary endpoint was the WSI difference from before treatment to Changes in International Normalized Ratio, warfarin doses, and time in therapeutic range were measured.

Results: In the final sample of 43 patients, the mean WSI decreased during treatment from 0.53 to 0.40, or 25.2%. After treatment, the mean WSI rose to 0.51. Although the mean weekly warfarin dose increased from 40.3 to 44.6 mg during treatment, the mean International Normalized Ratio decreased from 2.40 to 1.96, recovering to 2.59 after treatment. The time spent in therapeutic range decreased from 74.1% before treatment to 39.8% during treatment and back to 64.9% 12 weeks posttreatment.

Conclusion: When elbasvir-grazoprevir was added to stable warfarin anticoagulation, warfarin sensitivity decreased significantly during treatment and returned to baseline after treatment.

Keywords: anticoagulants; antiviral agents; chronic hepatitis C; drug interactions; warfarin; warfarin sensitivity.

PubMed Disclaimer

MeSH terms